The goal of this study is to evaluate the impact of implementing an AI-enabled clinical workflow tool (Viz COPD) on respiratory specialist follow up and clinical outcomes after an acute exacerbation.
Eligibility
Sex
ALL
Min age
40 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria:
* Patients aged 40 years or older at the time of arrival to the emergency department.
* Patients with a clinical diagnosis of COPD who present to the emergency department for a moderate or severe COPD exacerbation.
* A moderate exacerbation is defined as an acute exacerbation requiring either systemic corticosteroids (such as intramuscular, intravenous or oral) and/or antibiotics.
* A severe exacerbation is defined as an acute exacerbation requiring hospitalization, or observation for \>24 hours in emergency department/urgent care facility or resulting in death.
* Patients on dual (LABA/LAMA, LABA/ICS, LAMA/ICS) or triple (LABA/LAMA/ICS) long-acting bronchodilator inhalers.
Exclusion Criteria:
* Patients on bronchodilator inhaler monotherapy.
* Patients leaving against medical advice or expiring during hospitalization.
* Patients with tracheostomy.
* Patients with advanced cancer.
* Patients who have received a lung transplant.
* Discharge to hospice care.
* Transfer to another hospital.
Primary outcome measure(s)
To assess the effect of a digital health tool implementation on patient follow up with a respiratory specialist within 30 days after discharge for an acute COPD exacerbation resulting in an emergency department visit or hospitalization. — From time of exacerbation to 30 days after discharge Proportion of patients with a respiratory specialist follow-up visit within 30 days after discharge in the experimental cohort compared to the control cohort.
To assess the effect of a digital health tool implementation on time to respiratory specialist follow-up after an acute COPD exacerbation resulting in an emergency department visit or hospitalization. — Up to 1 year Time from discharge to respiratory specialist follow-up visit in the experimental cohort compared to the control cohort.
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time on our Cookie Policy page. See also our Privacy Policy.